Core Viewpoint - The stock of Bohan Bio (06955) has dropped over 8% following the release of its interim results, reflecting investor concerns over declining profits despite revenue growth [1] Financial Performance - For the first half of the year, Bohan Bio reported revenue of RMB 393 million, an increase of 8.4% year-on-year [1] - Gross profit remained stable at RMB 283 million, showing no significant change compared to the previous year [1] - Profit attributable to the parent company decreased by 66.7% to RMB 20.514 million [1] Revenue Drivers - The increase in revenue was primarily driven by the sales of products (Bohyunuo, Bohyunbei, and Boluoga), which grew by 15.9% to RMB 385.3 million for the six months ending June 30, 2024 [1] Product Approval - On August 9, Bohan Bio announced that its self-developed product, Bohyunping (Dulaglutide injection), received approval from the National Medical Products Administration for use in blood sugar control in adult patients with type 2 diabetes [1] - Bohyunping is the first and currently the only approved biosimilar of Trulicity in the world, with no other domestic Dulaglutide injections having entered the market approval application stage [1] - The commercialization of Bohyunping in mainland China is being conducted in collaboration with Shanghai Pharmaceuticals Holding Co., Ltd. [1]
博安生物绩后跌超8% 上半年营收同比增超8% 期内纯利同比减少66.74%